This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Boehringer Ingelheim GmbH
Drug Names(s): BI44847
Description: BI 44847 is an oral, sodium-dependent glucose transporter-2 inhibitor (SGLT-2 inhibitor). SGLT-2 inhibitors express their therapeutic effect mainly by eliminating excess blood glucose via the urine.
Deal Structure: BI 44847 was in-licensed by Boehringer Ingelheim from Ajinomoto. Boehringer is the worldwide exclusive licensee for the rights to develop, manufacture and sell the drug. Ajinomoto retains a co-promotion right in japan.
Partners: Ajinomoto Pharmaceuticals Co., Ltd.
BI 44847 News
Pink Sheet In Brief: PhRMA state government relations
Additional information available to subscribers only: